Managed access opens overseas cancer therapy for U.S. dog case

CURRENT FULL VERSION: VMD Sciences is using a single canine oncology case to spotlight a bigger idea in animal health: global managed access as a route to therapies that aren’t commercially available in a veterinarian’s home market. In a February 3, 2026 announcement, the company said it supported U.S. veterinary oncologist Seth Glasser, DVM, in legally importing an EMA-approved tyrosine kinase inhibitor for Jetta, an 8-year-old mixed-breed dog with metastatic mast cell cancer. The treatment was described as unavailable in the U.S., and the company positioned the case as a compliant use of its Managed Access Program rather than a routine commercial prescription. (morningstar.com)

The background matters here. VMD Sciences has spent the past year publicly promoting veterinary expanded-access and managed-access pathways as a way to obtain investigational or foreign-approved therapies for animals with serious disease when standard options have been exhausted. In March 2025, the company announced a similar effort involving a dog with inoperable soft tissue sarcoma, describing expanded access as a legislated regulatory mechanism that can allow importation of non-domestic or experimental treatments under defined conditions. That framing mirrors a broader shift in veterinary medicine, where sponsors and specialty clinicians are increasingly exploring structured access programs that have long been more familiar in human health care. (businesswire.com)

The oncology context is also well established. Mast cell tumors are among the most common canine neoplasms, and tyrosine kinase inhibitors are already part of the treatment toolbox for select unresectable, recurrent, or metastatic cases. In the U.S., Palladia (toceranib phosphate) is FDA-approved for grade II or III cutaneous mast cell tumors, with or without regional lymph node involvement, while Europe also has masitinib approved for certain non-resectable mast cell tumors with confirmed mutated c-kit receptor status. Reviews of canine mast cell tumor management note that TKIs are used not only in labeled settings, but also more broadly in metastatic, rescue, and high-risk disease. (hospital.cvm.ncsu.edu)

What VMD Sciences has not publicly detailed is the exact product imported for Jetta, beyond describing it as an EMA-approved tyrosine kinase inhibitor. That limits how much clinicians can infer about mechanism, label alignment, dosing, or expected adverse-event profile. Still, the therapeutic concept is plausible. Recent veterinary literature continues to explore kinase inhibition beyond currently marketed U.S. options. A 2025 retrospective study of 35 dogs with mast cell tumors treated with imatinib reported a 77% overall clinical benefit rate, with median overall survival of 270 days and generally limited, self-limiting gastrointestinal and hematologic toxicities, though the authors emphasized that further study is needed. (pubmed.ncbi.nlm.nih.gov)

Expert reaction in this case appears to come mainly from the company and participants rather than independent outside commentators. In its prior sarcoma access announcement, VMD Sciences president Richard Falcha called expanded-access policies “game changers” for veterinary medicine, and the treating oncologist in that case said the process opened “a new door of possibilities” for animals in practice. Those comments underscore the appeal of access programs for specialists managing refractory disease, but they should also be read in context: these are promotional statements tied to a service provider, not peer-reviewed outcomes data or society guidance. (businesswire.com)

Why it matters: For veterinary professionals, the practical takeaway is that regulatory access may become a more important part of specialty oncology, especially when pet parents are seeking one more option after standard therapies fail. Managed access could expand the menu of treatment possibilities for difficult mast cell tumor cases, particularly if a drug is approved overseas, has a biologically relevant target, and can be imported compliantly for an individual patient. But these cases also raise familiar questions around evidence thresholds, informed consent, cost, logistics, monitoring, and pharmacovigilance. Access is not the same as approval, and case-level success stories shouldn’t be mistaken for proof that an imported therapy outperforms established options. The story also lands in a broader mast cell tumor moment. IDEXX said in January 2026 that it plans to expand its Cancer Dx Panel to include canine mast cell tumor detection beginning in mid-2026, with no change to sample requirements or the usual two- to three-day turnaround time, and to add mast cell tumor FNA cytology to its inVue Dx Cellular Analyzer so clinics can get slide-free, same-visit in-house results with optional remote pathologist review. That matters because mast cell tumors often look like ordinary skin masses and can be difficult to distinguish from benign lesions early, delaying diagnosis and treatment planning. On the treatment side, supportive care is also evolving: the FDA has renewed conditional approval of Jaguar Health’s Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced diarrhea in dogs through December 21, 2026, preserving an indication-specific option aimed at reducing chloride ion secretion and fluid loss without slowing intestinal transit. Because diarrhea can be a dose-limiting toxicity in canine oncology, tools that help maintain hydration, comfort, and protocol adherence may matter almost as much as access to the anticancer drug itself. (morningstar.com)

The story also lands at a moment when canine mast cell tumor management is evolving on multiple fronts. Alongside therapeutic access, diagnostics are improving, with companies such as IDEXX recently promoting tools aimed at earlier mast cell tumor detection and faster in-clinic decision-making. The Cancer Dx Panel, already used by more than 5,500 clinics primarily for lymphoma screening, is being positioned for use both in at-risk dogs during wellness care and in patients whose skin masses warrant further workup. Meanwhile, inVue Dx’s mast cell tumor application is the first step in a broader planned cytology menu expansion. Taken together, that points to a broader oncology trend: earlier identification, more targeted treatment selection, more attention to supportive care, and greater interest in matching individual patients to therapies that may sit outside traditional local formularies. (mdpi.com)

What to watch: The next signal will be whether VMD Sciences discloses additional case details, publishes outcomes, or expands managed access beyond isolated anecdotes into a repeatable channel for specialty practices. More broadly, veterinarians should watch for any movement toward formal U.S. development or approval of overseas oncology products already being used abroad for canine mast cell disease, because that would shift these therapies from exceptional access into standard clinical practice. It is also worth watching whether IDEXX’s new mast cell tumor diagnostics change how quickly suspicious skin masses are worked up in first-opinion practice, and whether Jaguar Health can convert Canalevia-CA1’s fifth and final year of conditional approval into full approval once its ongoing effectiveness study is complete. (morningstar.com)